神戸大学附属図書館デジタルアーカイブ
https://hdl.handle.net/20.500.14094/0100492114

このアイテムのアクセス数:36件（2025-04-25 13:14 集計）

閲覧可能ファイル 

ファイル フォーマット サイズ 閲覧回数 説明
0100492114 (fulltext) pdf 888 KB 22

メタデータ

ファイル出力

メタデータID
0100492114
アクセス権
open access
出版タイプ
Version of Record
タイトル
Serum Exosomes Expressing CD9, CD63 and HER2 From Breast-Cancer Patients Decreased After Surgery of the Primary Tumor: A Potential Biomarker of Tumor Burden
著者
Inubushi, Sachiko ; Kunihisa, Tomonari ; Kuniyasu, Marina ; Inoue, Shotaro ; Yamamoto, Mayuko ; Yamashita, Yuji ; Miki, Mayuko ; Mizumoto, Sachiko ; Baba, Motoi ; Hoffman, Robert M. ; Tanino, Hirokazu
著者ID
A1684
研究者ID
1000060585959
ORCID
0000-0003-0541-4942
KUID
https://kuid-rm-web.ofc.kobe-u.ac.jp/search/detail.html?systemId=90c3f2036b1b29fa520e17560c007669
著者名
Inubushi, Sachiko
犬伏, 祥子
イヌブシ, サチコ
所属機関名
医学研究科
著者ID
A2384
研究者ID
1000050839800
KUID
https://kuid-rm-web.ofc.kobe-u.ac.jp/search/detail.html?systemId=ecd9a2a1dfef24ce520e17560c007669
著者名
Kunihisa, Tomonari
國久, 智成
クニヒサ, トモナリ
所属機関名
医学部附属病院
著者名
Kuniyasu, Marina
著者名
Inoue, Shotaro
著者名
Yamamoto, Mayuko
著者名
Yamashita, Yuji
著者名
Miki, Mayuko
著者名
Mizumoto, Sachiko
著者名
Baba, Motoi
著者名
Hoffman, Robert M.
著者ID
A2053
研究者ID
1000050285392
著者名
Tanino, Hirokazu
谷野, 裕一
タニノ, ヒロカズ
所属機関名
医学部附属病院
言語
English (英語)
収録物名
Cancer Genomics & Proteomics
巻(号)
21(6)
ページ
580-584
出版者
International Institute of Anticancer Research
刊行日
2024-11
公開日
2024-11-13
抄録
Background/Aim: Exosomes are extracellular vesicles produced by both normal and cancer cells. Previous research has demonstrated that circulating exosomes derived from cancer cells may create a niche for future metastasis, distant from the primary tumor. In the present report, circulating exosomes were captured and quantified based on exosome-surface proteins in pre- and post-operative serum of breast cancer patients, focusing on the exosome markers CD9 and CD63, as well as HER2, a therapeutic target for breast cancer. Materials and Methods: Eight breast cancer patients were recruited, and their pre- and post-operative serum samples were analyzed for CD63 and CD9; or CD9 and human epidermal growth factor receptor-2 (HER2), double-positive exosomes. An ExoCounter with antibody-conjugated beads was used to capture serum-derived exosomes. Sera from patients with tumors larger than 10 mm were used for analysis. The resected breast cancer was also histopathologically analyzed for the presence of HER2. Results: CD63 and CD9 double-positive serum exosomes and CD9 and HER2 double-positive serum exosomes decreased after surgery in breast-cancer patients whose tumors expressed HER2, as determined by histopathological analysis. Conclusion: Serum exosomes expressing CD9, CD63 and HER2 are candidate biomarkers of tumor burden in HER2-positive breast-cancer patients.
キーワード
Exosomes
cancer cells
breast cancer
CD63
CD9
HER2
serum
mastectomy
tumor burden
biomarker
カテゴリ
医学研究科
医学部附属病院
学術雑誌論文
権利
© 2024 The Author(s). Published by the International Institute of Anticancer Research.
CC license
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International license.
関連情報
DOI
https://doi.org/10.21873/cgp.20474
PMID
39467625